About erdafitinib
FGFR kinase inhibitor
Used for
- Treats adults with advanced or metastatic urothelial cancer with susceptible FGFR3 changes, after prior treatment.
Usual adult dose
Starting dose: 8 mg by mouth once daily; increase to 9 mg after 14–21 days if blood phosphate permits.
Common side effects
- High phosphate levels
- Mouth sores, dry mouth, or taste changes
- Diarrhea, constipation, or nausea
- Dry eyes or blurred vision
Important warnings
- Requires testing for FGFR changes and regular blood phosphate checks.
- Can cause serious eye problems; regular eye examinations are required.
- May cause nail, skin, or mouth problems; report severe symptoms promptly.
- Avoid phosphate supplements and phosphate-containing medicines unless prescribed.
Pregnancy
Can harm an unborn baby. Avoid pregnancy during treatment and for 1 month after the last dose.
Breastfeeding
Do not breastfeed during treatment and for 1 month after the last dose.
Interactions
- Strong or moderate CYP2C9 or CYP3A4 inhibitors may increase erdafitinib exposure.
- Strong CYP3A4 inducers may reduce erdafitinib exposure.
- Erdafitinib can affect medicines transported by P-glycoprotein; separate dosing when directed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.